Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candi…
| Métrica | TLX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 53.0% | 57.4% | -4.3% |
| Operating Margin | 3.7% | -34.4% | +38.1% |
| Net Margin | -0.9% | -32.5% | +31.6% |
| FCF Margin | -5.3% | -12.6% | +7.2% |
| ROE | -1.7% | -39.2% | +37.5% |
| ROA | -0.6% | -30.9% | +30.3% |
| Current Ratio | 1.43 | 2.73 | -1.30 |
| Debt / Equity | 0.94 | 0.28 | +0.66 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -0.6% | — |
| ✗Flujo de caja operativo positivo | −$17M | $27M |
| ✗Rentabilidad sobre activos al alza | -0.6% | 3.6% |
| ✗Caja operativa/activos supera al ROA | -1.5% | ROA -0.6% |
| ✓Menos deuda a largo plazo | 33.7% | 36.3% |
| ✗Mejor liquidez (ratio corriente) | 1.43 | 2.78 |
| ✓Sin aumentar el nº de acciones | 338M | 345M |
| ✗Margen bruto al alza | 53.1% | 65.1% |
| ✓Rotación de activos al alza | 0.69 | 0.55 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -5.3% |
| ✗ROCE > 10 % | 3.2% |
| ✗Deuda neta/EBITDA < 3x | 5.1x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 24.5% |
Riesgo de quiebra (Altman Z 3.6): zona segura
Telix Pharmaceuticals Ltd cotiza a 10.69 USD y tiene una capitalización bursátil de $3.6B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud